| | 
Part, Chapter, Paragraph
1 I, 2. 10. 3 | innovation for the uptake of R&D.~Launching of a public
2 I, 2. 10. 4 | proprietary solutions and R&D resources can be created
3 I, 2. 11 | Suhrcke M, McKee M, Sauto Arce R, Tsolova S, Mortensen J (
4 II, 4. 3 | 3. References~ ~Anderson R, Kochanek K, et al. (1997):
5 II, 5. 2. 6 | values <120/80 mmHg (Vasan R et al, 2001). Also an isolated
6 II, 5. 2. 6 | Kirby A, Sourjina T, Peto R, Collins R, Simes R; Cholesterol
7 II, 5. 2. 6 | Sourjina T, Peto R, Collins R, Simes R; Cholesterol Treatment
8 II, 5. 2. 6 | Peto R, Collins R, Simes R; Cholesterol Treatment Trialists' (
9 II, 5. 2. 6 | 1278.~Lewington S, Clarke R, Qizilbash N, Peto R, Collins
10 II, 5. 2. 6 | Clarke R, Qizilbash N, Peto R, Collins R (2002): Prospective
11 II, 5. 2. 6 | Qizilbash N, Peto R, Collins R (2002): Prospective Studies
12 II, 5. 2. 6 | HW, Van Buchem FS, Buzina R, Djordjević BD, Dontas AS,
13 II, 5. 2. 6 | Lewington S, Whitlock G, Clarke R, Sherliker P, Emberson J,
14 II, 5. 2. 6 | Halsey J, Qizilbash N, Peto R, Collins R (2007): Prospective
15 II, 5. 2. 6 | Qizilbash N, Peto R, Collins R (2007): Prospective Studies
16 II, 5. 2. 7 | Manheim LM, Dyer AR, Wang R, Lubitz J et al (2005):
17 II, 5. 2. 7 | Ferrario M, Chiodini P, Sega R, and Stamler J (2006): Favorable
18 II, 5. 2. 7 | Mattiello A, Pilotto L, Sega R, Giampaoli S, Stamler J (
19 II, 5. 2. 7 | Leal J, Luengo-Fernandez R and Gray A (2005): European
20 II, 5. 3. 7 | SWITZERLAND~Yes~Source: Haward R, Borras MJ (2007)~ ~ ~Important
21 II, 5. 3. 9 | Berrino F, De Angelis R, Sant M, Rosso S, Bielska-Lasota
22 II, 5. 3. 9 | 592.~ ~Gatta G, Capocaccia R, Stiller C, Kaatsch P, Berrino
23 II, 5. 3. 9 | Specific Issues.~ ~Haward R, Borras MJ (2007): Portuguese
24 II, 5. 3. 9 | Quinn M, Mugno E, Capocaccia R, Grosclaude P, and the EUROCARE
25 II, 5. 3. 9 | Micheli A, Capocaccia R, Martinez C, Mugno E, Coebergh
26 II, 5. 3. 9 | Verdecchia A, Capocaccia R, Gatta G, Micheli A, Santaquilani
27 II, 5. 4. 8 | P, Battlogg, K, Gfrerer, R, Trajanoski, Z, Wach, P,
28 II, 5. 4. 8 | AD, Boyle DI, MacAlpine R, Emslie-Smith A, Jung RT,
29 II, 5. 5.Int(15)| ME, Delespaul P, Fuhrer R, Hooijer C, Lawlor BA, Kivela
30 II, 5. 5. 1 | MC, Bernert S, Bruffaerts R, Brugha TS, Bryson H (2004a).
31 II, 5. 5. 1 | Bernert S, Brugha T, de Graaf R, Bruffaerts R, Lépine JP,
32 II, 5. 5. 1 | de Graaf R, Bruffaerts R, Lépine JP, de Girolamo
33 II, 5. 5. 1 | Psychiatry 6(3):168-76.~ ~Kessler R, Nelson C, McGonagle K, Liu G (
34 II, 5. 5. 2 | 2008)~ ~Haan MN and Wallace R (2004): Can dementia be
35 II, 5. 5. 3 | 10.1002/eat.1022.~Levey R (2006): Anorexia Nervosa.
36 II, 5. 5. 3 | Currie CR, Morgan A, Smith R, Settertobulte W, Samdal
37 II, 5. 5. 3 | ahead of print.~Bottlender R (2006): For and against: “
38 II, 5. 5. 3 | Rossi G, Ghilardi A, Pioli R (2007): The stigma of schizophrenia
39 II, 5. 5. 3 | Demyttenaere K, Bruffaerts R, Posada-Villa J, Gasquet
40 II, 5. 5. 3 | Borges G, Lara C, de Graaf R, Ormel J, Gureje O, Shen
41 II, 5. 5. 3 | Wagner M, Maier W, Bottlender R, Möller HJ, Gaebel W, Wölwer
42 II, 5. 5. 3 | Healy D, Harris M, Tranter R, Gutting P, Austin R, Jones-Edwards
43 II, 5. 5. 3 | Tranter R, Gutting P, Austin R, Jones-Edwards G, Roberts
44 II, 5. 5. 3 | McGraw-Hill Education.~Kohn R, Saxena S, Levav I, Saraceno
45 II, 5. 5. 3 | A, Schürmann A, Michels R, Malchow CP, Dilling H (
46 II, 5. 5. 3 | 333, 2007.~htt df~Vauth R (2006): Psychosocial Interventions
47 II, 5. 5. 3 | suppl. 10)~Knapp M, Romeo R, Beecham J (2007): The economic
48 II, 5. 5. 3 | 63:1002-1007.~Sidenvall R, Forsgren L, Blomquist HK,
49 II, 5. 5. 3 | Paediatr 82:60-65.~Sidenvall R, Forsgren L, Heijbel J (
50 II, 5. 5. 3 | L, Tonon C, D’Alessandro R, on behalf of the Bologna
51 II, 5. 5. 3 | Sudomoina M, Turetskaya R (1995): Epidemiology of
52 II, 5. 5. 3 | Myhr KM, Nyland H, Midgard R (2004): Multiple sclerosis
53 II, 5. 5. 3 | Psychiatry 73;256-260.~Doll R, Hill AB (1966). Mortality
54 II, 5. 5. 3 | Gerry E, Johnson M, Williams R (2002). A prospective study
55 II, 5. 5. 3 | B, Lemesle M, Urbinelli R, Giroud M (2000): Incidence
56 II, 5. 5. 3 | Fernández-Buey N, Fernández-Herranz R (1999): Prevalence of multiple
57 II, 5. 5. 3 | Neurol 246:170-174.~Totaro R, Marini C, Cialfi A, et
58 II, 5. 5. 3 | De Hooghe MB, Vlietnick R, Carton H (1994): Prevalence
59 II, 5. 5. 3 | WHO, Geneve.~Zivadinov R, Iona L, Monti-Bragadin
60 II, 5. 5. 3 | Rodriguez J, Molina JA, Gabriel R, Morales JM (2003): Prevalence
61 II, 5. 5. 3 | 345.~Bermejo F, Gabriel R, Vega S, Morales JM, Rocca
62 II, 5. 5. 3 | 2):242-249.~D’Alessandro R, Gamberini G, Granieri E,
63 II, 5. 5. 3 | Singer M, Koehne-Volland R, Szucs T, Rathay B, Scholz
64 II, 5. 5. 3 | Dorsey ER, Constantinescu R, Thompson JP, Biglan KM,
65 II, 5. 5. 3 | MA, Morris JG, Traficante R, Reid WG, O’Sullivan DJ,
66 II, 5. 5. 3 | JG, Reid WG, Trafficante R (2005): Sydney Multicenter
67 II, 5. 5. 3 | Spottke E, Siebert U, Dodel R (2005): Cost of Parkinson’
68 II, 5. 5. 3 | 534-536.~Nath U, Thomson R, Wood R, Ben-Shlomo Y, Lees
69 II, 5. 5. 3 | Nath U, Thomson R, Wood R, Ben-Shlomo Y, Lees A, Rooney
70 II, 5. 5. 3 | P, Trenkwalder C, Dodel R, Wittchen HU (2008): Cognitive
71 II, 5. 5. 3 | Pinna L, Aiello I, Tola R, De Bastiani P, Pirisi A,
72 II, 5. 5. 3 | Berger K, Koehne-Volland R, Rieke J, Simonow A, Brandstaedter
73 II, 5. 5. 3 | Oertel WH, Ulm G, Dodel R (2005): Cost of illness
74 II, 5. 5. 3 | 836.~Sutcliffe RL, Prior R, Mawby B, McQuillan WJ (
75 II, 5. 5. 3 | Campenhausen S, Bornschein B, Wick R, Botzel K, Sampaio C, Poewe
76 II, 5. 5. 3 | Siebert U, Berger K, Dodel R (2005): Prevalence and incidence
77 II, 5. 6. 6 | 6.6. References~ ~Altman R, Asch E, Bloch D, Bole G,
78 II, 5. 6. 6 | Christy W, Cooke TD, Greenwald R, Hochberg M, . (1986) Development
79 II, 5. 6. 6 | PE, Sisitsky T, Auerbach R, Wanke LA, Buatti MC (2000):
80 II, 5. 6. 6 | 878-882~Combe B, Landewe R, Lukas C, Bolosiu HD, Breedveld
81 II, 5. 6. 6 | J, Pearson N, Greenwood R, Frankel S (2003): Population
82 II, 5. 6. 6 | Giannini EH, Heyse SP, Hirsch R, Hochberg MC, Hunder GG,
83 II, 5. 6. 6 | Albertson G, Price D, Swaney R, Anderson S, Anderson RJ (
84 II, 5. 6. 6 | Purdie D, Reid DM, Rowe R, Woolf AD, Wallace WA (2001):
85 II, 5. 6. 6 | Feeney A, Head J, Canner R, North F, Marmot M (1995):
86 II, 5. 6. 6 | Symmons D, Turner G, Webb R, Asten P, Barrett E, Lunt
87 II, 5. 7. 7 | Dacco V, Testa S, Bonaudo R, Claris-Appiani A, Taioli
88 II, 5. 7. 7 | FW, Boersma C, de Vries R, Hillege HL, van Gilst WH,
89 II, 5. 7. 7 | Van VJ, Klebe B, Middleton R, et al (2007): Chronic kidney
90 II, 5. 8. 7 | Hedlund U, Nilsson T, Flodin R, and Järvholm B (2004):
91 II, 5. 8. 7 | Marinoni A, Viegi G, de Marco R (2003): Chronic cough and
92 II, 5. 8. 7 | M, Aldington S, Beasley R (2006): Epidemiology and
93 II, 5. 8. 7 | 27: 188-207.~ ~Dal Negro R, Rossi A, Cerveri I (2003):
94 II, 5. 8. 7 | 97: s43-50.~ ~De Marco R, Accordini S, Cerveri I,
95 II, 5. 8. 7 | in Europe”. Loddenkemper R, Gibson GJ, Sibille Y eds.
96 II, 5. 8. 7 | Gislason T, Lindberg E, Hallin R, Ulrik CS, Brondum E,Nieminen
97 II, 5. 8. 7 | AC, Ronmark E, Lundgren R, Larsson LG, Lundback B (
98 II, 5. 8. 7 | Heaney L, Gingles J, Shepherd R, Kee F, Patterson C, MacMahon
99 II, 5. 8. 7 | Kromhout H, Garcia-Esteban R, Radon R, Jarvis D, Toren
100 II, 5. 8. 7 | Garcia-Esteban R, Radon R, Jarvis D, Toren K, Künzli
101 II, 5. 9. FB | References~ ~Plumb J, Brawer R, Brisbon N (2007): The interplay
102 II, 5. 9. 7 | Anderson HR, Ruggles R, Strachan DP, Austin JB,
103 II, 5. 9. 7 | 10S73-10S75~ ~Bousquet PJ, Hooper R, Kogevinas M, Jarvis D,
104 II, 5. 9. 7 | 111(2):402-7.~ ~De Marco R (2002): Incidence and remission
105 II, 5. 9. 7 | Ronmark E, Wickens K, Sporik R, Woodfolk JA, Platts-Mills
106 II, 5. 9. 7 | MA, Silvestri M, Olcese R, Pistorio A, Rossi GA. (
107 II, 5. 9. 7 | Fabian D, Holt S, Beasley R, Global Initiative for Asthma (
108 II, 5. 9. 7 | 946~ ~To E, Tosca-Segura R, Arn A (2002): Incidence
109 II, 5. 9. 7 | 636~ ~Verlato G, de Marco R (2003): Is the prevalence
110 II, 5. 10. 7 | 10.7. References~ ~Asero R, Ballmer-Weber BK, Beyer
111 II, 5. 10. 7 | Beyer K, Conti A, Dubakiene R, Fernandez-Rivas M, Hoffmann-Sommergruber
112 II, 5. 10. 7 | RSH, Stahl Skov P, van Ree R, Vlieg-Boerstra BJ, Hiller
113 II, 5. 10. 7 | Vlieg-Boerstra BJ, Hiller R, Hourihane JO, Kowalski
114 II, 5. 10. 7 | 50(7):633-637):~ ~Gupta R, Sheikh A, Strachan D, Ross
115 II, 5. 10. 7 | Knibb RC, Booth DA, Platts R, Booth IW, McDonald A (2005):
116 II, 5. 10. 7 | Botjes E, Crevel RWR, van Ree R (2007): The prevalence,
117 II, 5. 10. 7 | 62 (7), 717–722.~ ~Rona R, Keil T, Summers C, Gislason
118 II, 5. 10. 7 | Ciclitira PJ, Van Eckert R, Feighery C, Janssen FW,
119 II, 5. 10. 7 | Méndez E, Mothes T, Troncone R, Wieser H (2001): Analysis
120 II, 5. 10. 7 | Bannon G, Cockburn A, Crevel R, Fitzpatrick J, Mills C,
121 II, 5. 11. 3 | pierced with gold earrings (R Silva et al, 1997). Silver
122 II, 5. 11. 3 | Alanko K, Harvima RJ, Jolanki R, Kalimo K, Lahti A, Lammintausta
123 II, 5. 11. 3 | Laukkanen A, luukkaala T, Riekki R, Turjanmaa K, Varjonen E,
124 II, 5. 11. 3 | Dermatitis, 2003; 49:107–108.~R Silva, F Pere a, O Bord o,
125 II, 5. 11. 7 | Dermatol 2007;25:535-546.~ ~Hay R (2005): Literature review.
126 II, 5. 11. 7 | 371–373.~ ~Mar A, Marks R (2000): Prevention of atopic
127 II, 5. 11. 7 | Weismann K, Krakauer R, Wanscher B (1980): Prevalence
128 II, 5. 15. 6 | D, Israeli A, Chertkoff R, Zimran A (2006): National
129 II, 7. 7 | 15 April 2008].~ ~Bauer R, Nossek G, Steiner M (2007):
130 II, 7. 7 | D, Lormand JD, Waxweiler R (Eds.) (2006): Developing
131 II, 8. 2. 1 | Lennox N, Beange H, Davis R, et al. Management Guidelines –
132 II, 8. 2. 1 | Tasse, M.J., Thompson, J.R., Verdugo, M-A, Wehmeyer,
133 II, 8. 2. 1 | Bainbridge D, Cooper S-A, Davis R, Fujiura G, Heller T, Holland
134 II, 8. 2. 1 | Björkman, M., Ceccotto, R., Kamper, M., Weber, G.,
135 II, 8. 2. 2 | Pokharel GP, Pararajasegaram R, Etya’ale D, Négrel A-D,
136 II, 8. 2. 2 | Kocur I, Pararajasegaram R, Pokharel GP and Mariotti
137 II, 8. 2. 2 | Négrel A-D, Pararajasegaram R, Dadzie KY. Global data
138 II, 9. 1. 1 | registers.~ ~ ~(C=core, R=recommended, F=for further
139 II, 9. 1. 1 | vital status, plurality~R: Prevalence of selected
140 II, 9. 1. 1 | selected congenital anomalies~R: Distribution of APGAR score
141 II, 9. 1. 1 | by age, mode of delivery~R: Maternal mortality by cause
142 II, 9. 1. 1 | mortality by cause of death~R: Prevalence of severe maternal
143 II, 9. 1. 1 | Distribution of parity~R: Percentage of women who
144 II, 9. 1. 1 | who smoke during pregnancy~R: Distribution of mothers’
145 II, 9. 1. 1 | presentation, prev. Caesarean~R: Percentage of all pregnancies
146 II, 9. 1. 1 | following fertility treatment~R: Distribution of timing
147 II, 9. 1. 1 | timing of 1st antenatal visit~R: Distribution of births
148 II, 9. 1. 1 | mode of onset of labour~R: Distribution of place of
149 II, 9. 1. 1 | Distribution of place of birth~R: Percentage of infants breast-feeding
150 II, 9. 1. 1 | 186(2):274-8.~Bertollini R, DiLallo D, Spadea T, Perucci
151 II, 9. 1. 1 | Yang H, Platt RW, Sauve R, Liston R (2000): The contribution
152 II, 9. 1. 1 | Platt RW, Sauve R, Liston R (2000): The contribution
153 II, 9. 1. 1 | Yang H, Platt RW, Sauve R, Liston R (2000a): The contribution
154 II, 9. 1. 1 | Platt RW, Sauve R, Liston R (2000a): The contribution
155 II, 9. 1. 1 | Cuttini M, Petrou S, Agostino R, et al (2007): Characteristics
156 II, 9. 1. 1 | Schuitemaker NW, Brand R, van Dongen PW, Bennebroek
157 II, 9. 1. 2 | LM, Lowry RB, McDonnell R, Metneki J, Poetzsch S,
158 II, 9. 1. 2 | Gillerot Y, Baguette A, Gjergja R, Barisic I, Christiansen
159 II, 9. 1. 2 | Steinbicker V, Roesch C, McDonnell R, Scarano G, Calzolari E,
160 II, 9. 1. 2 | Riano-Galan I, Gatt M, McDonnell R, Nelen V and Stone D (2005c): "
161 II, 9. 1. 2 | De Walle H, Knill-Jones R, Candela S, Dale I, Danaché
162 II, 9. 1. 2 | Garcia-Minaur S, Physick N, Tenconi R, Wiesel A, Calzolari E,
163 II, 9. 2. 7 | R.M., Orlos, J.B., Knapp, J.R. (1976): Physical attractiveness,
164 II, 9. 2. 7 | Fabian D, Holt S, Beasley R (2004?): Global Burden of
165 II, 9. 3. 1 | McKinlay, J. & Krane, R. (1999) The likely worldwide
166 II, 9. 3. 1 | Hobbs, F.D.R. Fourcade R. Kiemeney , L, Lee C. and
167 II, 9. 3. 1 | Osteoporosis in Men. In Kirby, R.S Carson, CC, Kirby, MG &
168 II, 9. 3. 1 | V Shekelle, P Hopkins Jr R. Forciea, MA Owens, DK (
169 II, 9. 3. 1 | Verlato G, Calabrese R, De Marco R (2002): (Abstract)
170 II, 9. 3. 1 | G, Calabrese R, De Marco R (2002): (Abstract) Correlation
171 II, 9. 3. 2 | 186(2):274-8.~ ~Bertollini R, DiLallo D, Spadea T, Perucci
172 II, 9. 3. 2 | Yang H, Platt RW, Sauve R, Liston R (2000): The contribution
173 II, 9. 3. 2 | Platt RW, Sauve R, Liston R (2000): The contribution
174 II, 9. 3. 2 | Cuttini M, Petrou S, Agostino R, et al (2007): Characteristics
175 II, 9. 3. 2 | Schuitemaker NW, Brand R, van Dongen PW, Bennebroek
176 II, 9. 3. 3 | al, 2006), Ireland (Layte R et al, 2006) were used,
177 II, 9. 3. 3 | under 25, it is 17 (Layte R et al, 2006). For what concerns
178 II, 9. 3. 3 | general population (Layte R et al, 2006).~ ~Predictors
179 II, 9. 3. 3 | first intercourse (Layte R et all, 2006). In Italy
180 II, 9. 3. 3 | Roberts C, Morgan A, Smith R, Settertobultr W, Samdal
181 II, 9. 3. 3 | Wellings K, Weiss HA, Hayes R (2005): Increased condom
182 II, 9. 3. 3 | Aids 19:1215-23.~Layte R, McGee H, Qual A, Rundle
183 II, 9. 3. 3 | Donnelly C, Mulcahy F, Conroy R (2006): The Irish Study
184 II, 9. 3. 3 | Prevention.~Shepherd J, Weston R, Peersman G, Napuli IZ,
185 II, 9. 3. 3 | Wilkinson P, French R, Kane R, et al (2006) Teenage
186 II, 9. 3. 3 | Wilkinson P, French R, Kane R, et al (2006) Teenage conceptions,
187 II, 9. 4. 7 | 618-624(7)~Billings, J. R., Alaszewski A.M., Coxon
188 II, 9. 5. 6 | Eurostat, UNECE/WHO~ ~Borland R (1990): Slip-ups and relapse
189 II, 9. 5. 6 | accessed 12.07.07)~ ~Iredale R, Reid A, EIWH (2007): Discrimination
190 III, 10. 1. 3 | Alcohol 5:373-402.~Beaglehole R (2004): Determinants of
191 III, 10. 1. 3 | Health. (Edited by: Detels R, McEwen J, Beaglehole R,
192 III, 10. 1. 3 | R, McEwen J, Beaglehole R, Tanaka H.) New York, Oxford
193 III, 10. 1. 3 | Burke V, Beilin LJ, Milligan R, Thompson C (1995): Assessment
194 III, 10. 1. 3 | Health. (Edited by: Detels R, McEwen J, Beaglehole R,
195 III, 10. 1. 3 | R, McEwen J, Beaglehole R, Tanaka H.) New York, Oxford
196 III, 10. 1. 3 | Health. (Edited by: Detels R, McEwen J, Beaglehole R,
197 III, 10. 1. 3 | R, McEwen J, Beaglehole R, Tanaka H.) New York, Oxford
198 III, 10. 1. 3 | Lindenberg CS, Solorzano R, Kelley M, Darrow V, Gendrop
199 III, 10. 1. 3 | Rehm J, Ashley MJ, Room R, Single E, Bondy S, Ferrence
200 III, 10. 1. 3 | Single E, Bondy S, Ferrence R, Giesbrecht N (1996): On
201 III, 10. 1. 3 | 41(4):455-463.~Velleman R (1992a): Intergenerational
202 III, 10. 1. 3 | 27(3):253-280.~Velleman R (1992b): Intergenerational
203 III, 10. 2. 1 | Dicato M, Diehl L, Doll R, Franceschi S, Gillis CR,
204 III, 10. 2. 1 | AE, Geurts JJM, Crialesi R, Grötvedt L (2000): Educational
205 III, 10. 2. 1 | Janson C, Künzli N, de Marco R, Chinn S, Jarvis D, Svanes
206 III, 10. 2. 1 | Svanes C, Heinrich J, Jõgi R, Gislason T, Sunyer J, Ackermann-Liebrich
207 III, 10. 2. 1 | Available at: htt ~ ~Peto R, Lopez AD, Boreham J, Thun
208 III, 10. 2. 1 | Prevention.~ ~Babor TF, Caetano R, Casswell S, Edwards G,
209 III, 10. 2. 1 | Hill L, Holder HD, Homel R, Österberg E, Rehm J, Room
210 III, 10. 2. 1 | Österberg E, Rehm J, Room R and Rossow I (2003): Alcohol:
211 III, 10. 2. 1 | Shults RA, Sleet DA, Compton R, Nichols JL (2005): Effectiveness
212 III, 10. 2. 1 | Journal, 316: 1636-42.~ ~Ljung R, Peterson S, Hallqvist J,
213 III, 10. 2. 1 | Brettschneider WD, Naul R (2004): Study on young people’
214 III, 10. 2. 1 | 2):260–275.~ ~Sonstroem R (1984): Exercise and self-esteem.
215 III, 10. 2. 1 | Madrid . Requejo A., Ortega R. 2002~Sweden~Dietary habits
216 III, 10. 2. 1 | 1472.~ ~Boros J, Németh R, Vitrai J (2002): Országos
217 III, 10. 2. 1 | Roberts C, Morgan A, Smith R, Settertobulte W, Samdal
218 III, 10. 2. 1 | Reviews 7:233-237.~ ~Dolman R, Kingdon A, Roberts C, eds (
219 III, 10. 2. 1 | V, Paalanen L, Prättälä R (2007): Suaugusių lietuvos
220 III, 10. 2. 1 | Helakorpi S, Patja S, Prättälä R, Uutela A (2007): Suomalaisen
221 III, 10. 2. 1 | James WPT, Jackson-Leach R, nì Mhurchu C, Kalamara
222 III, 10. 2. 1 | Yang H, Platt RW, Usher R, McNamara H, Joseph KS,
223 III, 10. 2. 1 | Lobstein T, Baur L, Uauy R, for the IASO International
224 III, 10. 2. 1 | V, Paalanen L, Prättälä R (2005): Latvijas iedzïvotäju
225 III, 10. 2. 1 | Hermann D, Boros J, Németh R, Kéki Z (2005): Táplálkozási
226 III, 10. 2. 1 | Primatesta P, Chinn S, Rona R, Falascheti E (2005): Overweight
227 III, 10. 2. 1 | Trichopoulou A, Tumino R, Navarro Sanchez C, Martinez
228 III, 10. 2. 1 | Pettersson U, Palmqvist R, Van Guelpen B, Bingham
229 III, 10. 2. 1 | Pala V, Masala G, Tumino R, Sacerdote C, Del Pezzo
230 III, 10. 2. 1 | Welch AA, Krogh V, Luben R, Allen N, Overvad K, Tjonneland
231 III, 10. 2. 1 | Janzon L, Jansson J, Luben R, Spencer EA, Overvad K,
232 III, 10. 2. 1 | V, Zavitsanos X, Tumino R, Galasso R, Bueno-De-Mesquita
233 III, 10. 2. 1 | Zavitsanos X, Tumino R, Galasso R, Bueno-De-Mesquita HB, Ocke
234 III, 10. 2. 4 | Schröder P, Brand H, Zimmern R (2006): Getting Ready for
235 III, 10. 2. 4 | Chakravarti A., Gesteland R, Walters L (1998): New Goals
236 III, 10. 2. 4 | 317.~ ~Lunshof JE, Chadwik R, Vorhaus DB, Church GM (
237 III, 10. 2. 4 | nrg2360: 2-7.~ ~Roberts, R, Sullivan P, Joyce P, Kennedy
238 III, 10. 2. 4 | Spink C, Davis S, Bosch R, Scarpa A, Zhang Y, Severson
239 III, 10. 2. 5 | Puura K, Luoma I, Salmelin R, Davis H, Tsiantis J, Ispanovic-Radojkovic
240 III, 10. 2. 5 | Paradisiotou A, Vizakou S, Roberts R, Cox A, Day C (2002) The
241 III, 10. 3. 1 | Tampere, 2006.~Bray F, Sankila R, Ferlay J, Parkin DM (2002):
242 III, 10. 3. 1 | Bochicchio F, Deo H, Falk R, Forastiere F, Hakama M,
243 III, 10. 3. 1 | Whitley E, Wichmann HE, Doll R, (2005): Radon in homes
244 III, 10. 3. 1 | 92, no. 4, 371-8.~Lucas R, McMichael T, Smith W, Armstrong
245 III, 10. 3. 1 | Med., 49, 266-274.~Torfs R (2003). Kwantificering van
246 III, 10. 3. 1 | Villeneuve PJ, Morrison HI, Lane R (2007). Radon and lung cancer
247 III, 10. 3. 2 | Morrison, S Rauch, C McLeod, R Ma, S Caroli, A Alimonti,
248 III, 10. 3. 2 | Ravindra, K, L Bencs, R van Grieken (2004): Platinum
249 III, 10. 3. 2 | Vieth B, Rüdiger, R, Ostermann, B, Mielke, H. (
250 III, 10. 4. 2 | 2005. pp.286.~ ~Kallenborn R. (2006): Persistent organic
251 III, 10. 4. 2 | Inoue, K, Okada, F, Ito, R, Kato, S, Sasaki, S, Nakajima,
252 III, 10. 4. 2 | F, Yoshimura, Y, Kishi, R, Nakazawa, H.(2004). Perfluorooctane
253 III, 10. 4. 2 | 1204-1207~ ~Kallenborn, R. and A. DiGuardo (2006).
254 III, 10. 5. 1 | Kim HS, Mccarthy H, Oren R, Finzi C, EllsWorth DS,
255 III, 10. 5. 1 | 569.~Milstead TM, Miles R, Röbbel N. (2006): Housing
256 III, 10. 5. 1 | Richardson G, Eick S, Jones R (2005): How is the indoor
257 III, 10. 5. 1 | children (1257-RP).~ ~Walinder R, Gunnarsson K, Runeson R,
258 III, 10. 5. 1 | R, Gunnarsson K, Runeson R, Smedje G (2007) Physiological
259 III, 10. 5. 3 | Geneva. htt tm~Karasek, R. A. & Theorell, T. (1990).
260 III, 10. 5. 3 | Leal J, Luengo-Fernandez R, Gray A, Peterson S, Rayner
261 III, 10. 6. 1 | Godeau E, Roberts C, Smith R, Currie D, Picket W, Richter
262 III, 10. 6. 1 | Catalogue/20080617_1.~ ~De Vogli R, Chandola T, Marmot MG (
263 III, 10. 6. 1 | 128(2):370-80.~ ~Kessler R, McLeod J, Wethington E.
264 III, 10. 6. 1 | 1017~Van Dijk J, Manchin R, Van Kesteren J, Hideg G,
265 IV, 11. 5. 6 | substances~ ~· Recommendation No. R (99) 21 of the Committee
266 IV, 11. 5. 6 | and to Recommendation No. R (97) 5 on the protection
267 IV, 11. 6. 5 | References~ ~Altman S, Blendon R Eds. (1979): Medical Technology:
268 IV, 11. 6. 5 | Printing Office.~ ~Anderson R (2004): Health and health
269 IV, 11. 6. 5 | Public Health.~ ~Blendon R, Kim M, Benson JM (2001): "
270 IV, 11. 6. 5 | Health 13(1): 13-16.~ ~Brook R, McGlynn E et al. (1996): "
271 IV, 11. 6. 5 | Oncol 22: 2000-7.~ ~Busse R, Schreyogg J et al. (2006): "
272 IV, 11. 6. 5 | Science 9: 211-213.~ ~Busse R, Orvain J, Velasco M, Perleth
273 IV, 11. 6. 5 | Practice. K. Walshe and R. Boaden. Berkshire, Open
274 IV, 11. 6. 5 | 350(4): 406-410.~ ~Ervik R (1998): The Redistributive
275 IV, 11. 6. 5 | systems in Western Europe. R. B. Saltman, R. Busse and
276 IV, 11. 6. 5 | Western Europe. R. B. Saltman, R. Busse and J. Figueras.
277 IV, 11. 6. 5 | systems in Western Europe. R. B. Saltman, R. Busse and
278 IV, 11. 6. 5 | Western Europe. R. B. Saltman, R. Busse and J. Figueras.
279 IV, 11. 6. 5 | Practice. K. Walshe and R. Boaden. Berkshire, Open
280 IV, 11. 6. 5 | health care reform in Europe. R. B. Saltman, J. Figueras
281 IV, 11. 6. 5 | University Press.~ ~Richman R, Lancaster DR (2000): "The
282 IV, 11. 6. 5 | 5): 1589-606.~ ~Robinson R, Jakubowski E et al. (2005):
283 IV, 11. 6. 5 | performance. J. Figueras, R. Robinson and E. Jakubowski.
284 IV, 11. 6. 5 | Rosenthal MB, Fernandopulle R et al. (2004): "Paying for
285 IV, 11. 6. 5 | systems in Western Europe. R. B. Saltman, R. Busse and
286 IV, 11. 6. 5 | Western Europe. R. B. Saltman, R. Busse and J. Figueras.
287 IV, 11. 6. 5 | 320: 774-77.~ ~Westerling R (1996): “Studies of avoidable
288 IV, 11. 6. 5 | Assessment 1(Doc09).~ ~Kane, R. L. (1997). Understanding
289 IV, 11. 6. 5 | Vaughan, J.P., Morrow, R.H. Manual of Epidemiology
290 IV, 13. 7. 2 | expanding private investment in R&D; location advantages for
291 IV, 13. 7. 2 | location advantages for R&D and production facilities;
292 IV, 13. 9 | Köhler LI, Blair ME, Mechtler R (2003): Child Health Indicators
|
|
| |
